Table 2.
A summary of clinical trials registered at ClinicalTrials.gov involving oHSV variants. Access date: 13 February 2021.
| Variant | Combination Therapy | Clinical Trial Number | Status | Virus | Malignant Type | Phase | Year Posted |
|---|---|---|---|---|---|---|---|
| T-VEC | - | NCT00289016 | Completed | HSV-1 | Stage IIIC and IV melanoma | II | 2006 |
| - | NCT00289016 | Completed | HSV-1 | Stage IIIC and IV melanoma | II | 2006 | |
| - | NCT00769704 | Completed [89] | HSV-1 | Melanoma | III | 2008 | |
| Cisplatin + Radiation | NCT01161498 | Terminated | HSV-1 | Head and neck cancer | III | 2010 | |
| GM-CSF | NCT01368276 | Completed | HSV-1 | Melanoma | III | 2011 | |
| Ipilimumab | NCT01740297 | Active, not recruiting [90] | HSV-1 | Melanoma | I, II | 2012 | |
| - | NCT02014441 | Completed [87] | HSV-1 | Melanoma | II | 2013 | |
| Pembrolizumab | NCT02263508 | Active, not recruiting | HSV-1 | Melanoma | III | 2014 | |
| - | NCT02173171 | Enrolling by invitation | HSV-1 | Any tumor type | Unspecified | 2014 | |
| Resection surgery | NCT02211131 | Active, not recruiting | HSV-1 | Melanoma | II | 2014 | |
| Pembrolizumab | NCT02263508 | Active, not recruiting | HSV-1 | Melanoma | III | 2014 | |
| - | NCT02297529 | No longer available | HSV-1 | Stage IIIB-IVM1c melanoma | III | 2014 | |
| Chemotherapy or PV-10 | NCT02288897 | Terminated | HSV-1 | Melanoma | III | 2014 | |
| - | NCT02366195 | Completed | HSV-1 | Stage IIIb-IVM1c melanoma | II | 2015 | |
| Radiation | NCT02453191 | Active, not recruiting | HSV-1 | Soft tissue sarcoma | I, II | 2015 | |
| Pembrolizumab | NCT02626000 | Completed [91] | HSV-1 | Squamous cell carcinoma of the head and neck | I | 2015 | |
| - | NCT02574260 | Completed | HSV-1 | Melanoma | II | 2015 | |
| Pembrolizumab | NCT02509507 | Recruiting | HSV-1 | Liver cancer | I | 2015 | |
| - | NCT02658812 | Active, not recruiting | HSV-1 | Breast cancer | II | 2016 | |
| - | NCT02756845 | Recruiting | HSV-1 | Advanced non-CNS tumors | I | 2016 | |
| Radiation | NCT02819843 | Recruiting | HSV-1 | Melanoma, Markel cell carcinoma, and other tumors | II | 2016 | |
| Radiation | NCT02923778 | Recruiting | HSV-1 | Soft tissue sarcoma | II | 2016 | |
| Nivolumab | NCT02978625 | Recruiting | HSV-1 | Melanoma, lymphoma, lung cancer, and other | II | 2016 | |
| Pembrolizumab | NCT02965716 | Recruiting | HSV-1 | Stage III and IV melanoma | II | 2016 | |
| Paclitaxel | NCT02779855 | Active, not recruiting | HSV-1 | Triple negative breast cancer | I, II | 2016 | |
| - | NCT02658812 | Completed | HSV-1 | Breast cancer | II | 2016 | |
| - | NCT02910557 | Recruiting | HSV-1 | Melanoma and herpetic infection | Unspecified | 2016 | |
| TTI-621 | NCT02890368 | Terminated | HSV-1 | Solid tumors and mycosis fungoides | I | 2016 | |
| - | NCT03086642 | Recruiting | HSV-1 | Pancreatic cancer | I | 2017 | |
| - | NCT03064763 | Active, not recruiting | HSV-1 | Stage IIIb- IV melanoma | I | 2017 | |
| Pembrolizumab | NCT03069378 | Recruiting | HSV-1 | Sarcoma | II | 2017 | |
| Atezolizumab | NCT03256344 | Active, not recruiting | HSV-1 | Metastatic colorectal and breast cancers | I | 2017 | |
| Chemotherapy + Radiation | NCT03300544 | Recruiting | HSV-1 | Rectal cancer | I | 2017 | |
| Dabrafenib + Trametinib | NCT03088176 | Active, not recruiting | HSV-1 | Melanoma | I | 2017 | |
| - | NCT03458117 | Unknown | HSV-1 | Non-melanoma skin cancer | I | 2018 | |
| - | NCT03555032 | Active, not recruiting | HSV-1 | Sarcoma and melanoma | I, II | 2018 | |
| - | NCT03663712 | Recruiting | HSV-1 | Stage IV peritoneal malignancy | I | 2018 | |
| Autologous CD1c (BDCA-1)+ myeloid dendritic cells | NCT03747744 | Active, not Recruiting | HSV-1 | Melanoma | I | 2018 | |
| Nivolumab | NCT03597009 | Recruiting | HSV-1 | Lung cancer | I, II | 2018 | |
| - | NCT03430687 | Withdrawn | HSV-1 | Bladder carcinoma | I | 2018 | |
| - | NCT03714828 | Recruiting | HSV-1 | Squamous cell carcinoma | II | 2018 | |
| Chemotherapy or endocrine therapy | NCT03554044 | Recruiting | HSV-1 | Breast cancer | I | 2018 | |
| - | NCT03921073 | Recruiting | HSV-1 | Skin angiosarcoma | II | 2019 | |
| Atezolizumab | NCT03802604 | Recruiting | HSV-1 | Breast cancer | I | 2019 | |
| Pembrolizumab | NCT03842943 | Recruiting | HSV-1 | Melanoma | II | 2019 | |
| Dabrafenib + Trametinib | NCT03972046 | Withdrawn | HSV-1 | Melanoma | II | 2019 | |
| Pembrolizumab | NCT04068181 | Recruiting | HSV-1 | Melanoma | II | 2019 | |
| Panitumumab | NCT04163952 | Recruiting | HSV-1 | Squamous cell carcinoma of the skin | I | 2019 | |
| Nivolumab + Trabectedin |
NCT03886311 | Recruiting | HSV-1 | Sarcoma | II | 2019 | |
| - | NCT04065152 | Not yet recruiting | HSV-1 | Kaposi sarcoma | II | 2019 | |
| Ipilimumab + Nivolumab |
NCT04185311 | Recruiting | HSV-1 | Breast cancer | I | 2019 | |
| - | NCT04330430 | Recruiting | HSV-1 | Stage III and IV melanoma | II | 2020 | |
| TBI-1401 | - | NCT01017185 | Completed | HSV-1 | Squamous cell carcinoma of the skin, breast carcinoma, melanoma, head and neck cancer |
I | 2009 |
| Ipilimumab | NCT02272855 | Completed | HSV-1 | Melanoma | II | 2014 | |
| - | NCT02428036 | Completed | HSV-1 | Solid tumors | I | 2015 | |
| Ipilimumab | NCT03153085 | Completed | HSV-1 | Stage III and IV melanoma | II | 2017 | |
| Chemotherapy | NCT03252808 | Active, not recruiting | HSV-1 | Stage III and IV pancreatic cancer | I | 2017 | |
| G207 | - | NCT00028158 | Completed | HSV-1 | Brain cancer | I, II | 2001 |
| Radiation | NCT00157703 | Completed | HSV-1 | Malignant glioma | I | 2005 | |
| - | NCT02457845 | Active, not recruiting | HSV-1 | Brain cancer | I | 2015 | |
| - | NCT03911388 | Recruiting | HSV-1 | Brain cancers | I | 2019 | |
| - | NCT04482933 | Not yet recruiting | HSV-1 | High grade glioma | II | 2020 | |
| RP1 | Nivolumab | NCT03767348 | Recruiting | HSV-1 | Melanoma | I, II | 2018 |
| Cemiplimab | NCT04050436 | Recruiting | HSV-1 | Melanoma | II | 2019 | |
| - | NCT04349436 | Recruiting | HSV-1 | Squamous cell carcinoma | I | 2020 | |
| RP2 | Nivolumab | NCT04336241 | Recruiting | HSV-1 | Non-specified | I | 2020 |
| HSV-1716 | - | NCT00931931 | Completed [92] | HSV-1 | Non-CNS solid tumors | I | 2009 |
| - | NCT01721018 | Completed | HSV-1 | Malignant pleural mesothelioma | I, II | 2012 | |
| NV1020 | - | NCT00012155 | Completed | HSV-1 | Colorectal cancer | I | 2003 |
| - | NCT00149396 | Completed [93] | HSV-1 | Liver cancer and colorectal cancer | I, II | 2005 | |
| OrienX010 | - | NCT01935453 | Completed | HSV-1 | Melanoma, liver cancer, pancreatic cancer and lung cancer | I | 2013 |
| - | NCT03048253 | Unknown | HSV-1 | Melanoma | I-c | 2017 | |
| rRp450 | - | NCT01071941 | Recruiting | HSv-1 | Liver cancer | I | 2010 |
| M032 | - | NCT02062827 | Recruiting | HSV-1 | Brain cancers | I | 2014 |
| rQNestin | - | NCT03152318 | Recruiting | HSV-1 | Brain cancers | I | 2017 |
| C134 | - | NCT03657576 | Active, not recruiting | HSV-1 | Malignant glioma | I | 2018 |
| T3011 | NCT04370587 | Recruiting | HSV-1 | Head and neck cancer, Melanoma, Lung cancer, Soft tissue tumors and/or sarcoma, Solid tumors |
I | 2020 | |
| ONCR-177 | Pembrolizumab | NCT04348916 | Recruiting | HSV-1 | Various tumors | I | 2020 |
| OH2 | HX008 | NCT03866525 | Recruiting | HSV-2 | Solid and GI tumors | I, II | 2019 |
| Pembrolizumab | NCT04386967 | Recruiting | HSV-2 | Solid tumors | I, II | 2020 | |
| - | NCT04637698 | Recruiting | HSV-2 | Pancreatic cancer | I, II | 2020 | |
| HX008 | NCT04616443 | Recruiting | HSV-2 | Melanoma | I, II | 2020 |